TY  - JOUR
AU  - Alvarez-Larrán, Alberto
AU  - Garrote, Marta
AU  - Ferrer-Marín, Francisca
AU  - Pérez-Encinas, Manuel
AU  - Mata-Vazquez, M Isabel
AU  - Bellosillo, Beatriz
AU  - Arellano-Rodrigo, Eduardo
AU  - Gómez, Montse
AU  - García, Regina
AU  - García-Gutiérrez, Valentín
AU  - Gasior, Mercedes
AU  - Cuevas, Beatriz
AU  - Angona, Anna
AU  - Gómez-Casares, María Teresa
AU  - Martínez, Clara M
AU  - Magro, Elena
AU  - Ayala, Rosa
AU  - Del Orbe-Barreto, Rafael
AU  - Pérez-López, Raúl
AU  - Fox, Maria Laura
AU  - Raya, José-María
AU  - Guerrero, Lucía
AU  - García-Hernández, Carmen
AU  - Caballero, Gonzalo
AU  - Murillo, Ilda
AU  - Xicoy, Blanca
AU  - Ramírez, M José
AU  - Carreño-Tarragona, Gonzalo
AU  - Hernández-Boluda, Juan Carlos
AU  - Pereira, Arturo
AU  - MPN Spanish Group (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas)
PY  - 2022
DO  - 10.1002/cncr.34195
UR  - http://hdl.handle.net/10668/21618
T2  - Cancer
AB  - Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown. A retrospective, real-world analysis was performed on the outcomes...
LA  - en
KW  - hemorrhage
KW  - myelofibrosis
KW  - myeloproliferative neoplasms
KW  - polycythemia vera
KW  - ruxolitinib
KW  - therapy
KW  - thrombosis
KW  - Hemorrhage
KW  - Humans
KW  - Hydroxyurea
KW  - Leukemia, Myeloid, Acute
KW  - Neoplasms, Second Primary
KW  - Nitriles
KW  - Polycythemia Vera
KW  - Primary Myelofibrosis
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Retrospective Studies
KW  - Thrombosis
TI  - Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
TY  - research article
VL  - 128
ER  -